<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5574">
  <stage>Registered</stage>
  <submitdate>14/01/2011</submitdate>
  <approvaldate>14/01/2011</approvaldate>
  <nctid>NCT01278134</nctid>
  <trial_identification>
    <studytitle>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)</studytitle>
    <scientifictitle>INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment With a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir Boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) With or Without Copegus® in Interferon Naïve HCV Genotype 1 Infected Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-022067-35</secondaryid>
    <secondaryid>PP25213</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Copegus placebo
Treatment: drugs - RO5024048
Treatment: drugs - danoprevir
Treatment: drugs - peginterferon alfa-2a [Pegasys]
Treatment: drugs - ribavirin [Copegus]
Treatment: drugs - ritonavir

Experimental: Arm B Extension - All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.

Experimental: RO5024048 &amp; ritonavir-boosted danoprevir without Ribavirin (B) - 

Experimental: RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A) - 


Treatment: drugs: Copegus placebo
1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks

Treatment: drugs: RO5024048
1000 mg bid orally, up to 24 weeks

Treatment: drugs: danoprevir
100 mg bid orally, up to 24 weeks

Treatment: drugs: peginterferon alfa-2a [Pegasys]
180 mcg sc weekly, 24 weeks

Treatment: drugs: ribavirin [Copegus]
1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks

Treatment: drugs: ritonavir
100 mg bid orally, up to 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virological response, defined as undetectable HVC RNA measured by Roche COBAS TaqMan HCV test</outcome>
      <timepoint>24 weeks after end of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>1.5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Virological response (HCV RNA measured by Roche COBAS Taqman HCV test)</outcome>
      <timepoint>up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impact of Copegus (ribavirin) on efficacy of the direct-acting antiviral combination regimen: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome>
      <timepoint>1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of 12 and 24 weeks of treatment duration: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome>
      <timepoint>1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Plasma concentrations of danoprevir, ritonavir, RO4995855 (parent drug of RO5024048) and ribavirin</outcome>
      <timepoint>up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Viral resistance: HCV RNA sequencing and phenotypic analyses</outcome>
      <timepoint>up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of interleukin 28B genotype on efficacy: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome>
      <timepoint>1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life: SF-36 questionnaire, Fatigue Severity Scale</outcome>
      <timepoint>up to 36 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patient, &gt;/= 18 years of age

          -  Chronic Hepatitis C of &gt;/= 6 months duration at screening

          -  HCV genotype 1 and quantifiable HCV RNA at screening (Roche COBAS TaqMan HCV test)

          -  Naïve for treatment with interferon (pegylated or non-pegylated)

          -  Body Mass Index (BMI) 18-35 inclusive, minimum weight 45 kg

          -  Females of child-bearing potential and males with female partners of childbearing
             potential must use 2 forms of effective non-hormonal contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating women and males with female partners who are pregnant or
             lactating

          -  Decompensated liver disease or impaired liver function

          -  Cirrhosis or incomplete/transition to cirrhosis

          -  Non-hepatitis C chronic liver disease

          -  Hepatitis B or HIV infection

          -  History of neoplastic disease within the last 5 years, except for localized or in situ
             carcinoma of the skin

          -  History of pre-existing renal disease (except for nephrolithiasis) or severe cardiac
             disease

          -  History of drug or alcohol abuse within the last year or alcohol consumption of &gt; 2
             units per day; cannabinoid use is excepted</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>170</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt Am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This multicenter, randomized, double-blind, parallel group study will evaluate the safety and
      efficacy of the combination RO5024048 and ritonavir-boosted danoprevir with and without
      Copegus (ribavirin) in patients with chronic hepatitis C genotype 1. In arm A and B,
      interferon treatment-naïve patients will receive 1000 mg RO5024048 orally twice daily and 100
      mg danoprevir with 100 mg ritonavir orally twice daily plus either Copegus (1000 mg or 1200
      mg orally daily) or placebo for 12 weeks. Depending on viral response and treatment arm
      patients will be re-randomized to continue assigned treatment for additional 12 weeks or stop
      all treatment. The anticipated time on study treatment is up to 24 weeks plus a 24-week
      follow-up.

      As of 29. September 2011, Arm B patients (placebo-containing arm) will be offered, in
      conjunction with the current treatment, Pegasys (peginterferon alfa-2a) 180 mcg
      subcutaneously weekly plus Copegus 1000mg or 1200 mg orally daily for 24 weeks, with a
      24-week follow-up.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01278134</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>